Darrell H. Carney

Darrell H. Carney, PhD is an experienced entrepreneur and Adjunct Professor in the Department of Biochemistry & Molecular Biology at The University of Texas Medical Branch (UTMB). Early in his career, Dr. Carney received a National Cancer Institute (NCI) Career Development Award, discovered a class of cell surface receptors that stimulate cell proliferation and tissue regeneration, and developed a synthetic peptide, TP508, that activated these receptors to modulate inflammation and stimulate tissue repair. As an academic scientist, he raised over $13 million in NIH funding and has >90 publications and 28 patents. Dr. Carney established his first tissue repair company in 1995 and sold the company after completing early human clinical trials in diabetic foot ulcers and fracture repair. He established Chrysalis BioTherapeutics, Inc. in 2012 to develop drug products to prevent damaging effects of radiation. The company initially raised over $15 million in non-dilutive Government funding from NIH to fund drug development to mitigate effects of radiation and regenerate radiation damaged tissues. More recently, the company was awarded $1.5 million from NIAID to develop TP508 for COVID-19 treatment. Chrysalis has also received $21 million in the last 18 months as part of a $105 million BARDA contract to keep people alive in the event of a nuclear incident.